Search Results
Your search for The A matches 33134 pages
Showing 1 - 50Real-World Incidence and Management of Infusion-Related Reactions to Monoclonal Antibody Therapy
In a retrospective analysis published in JCO Oncology Practice, Smolders et al investigated the incidence and clinical course of infusion-related reactions among patients treated with at least one monoclonal antibody in routine practice. The study evaluated real-world data to compare observed...
Mifamurtide Plus Chemotherapy for Nonmetastatic High-Grade Osteosarcoma
In a pooled analysis of the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) trials reported in the Journal of Clinical Oncology, Palmerini et al found evidence of activity with the addition of mifamurtide to chemotherapy in patients with nonmetastatic high-grade osteosarcoma...
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
After 2 decades of practicing medicine across multiple disciplines and health systems, I’ve witnessed the dramatic transformation of patient-physician interactions, and none more dramatic than what I’m seeing in this era of artificial intelligence (AI) and its impact on cancer care. Early in my...
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
Patients with intermediate-stage hepatocellular carcinoma who received a vaccine of dendritic cells in addition to transarterial chemoembolization (TACE) and preconditioning cyclophosphamide experienced longer progression-free survival than those who received cyclophosphamide and TACE alone. The...
Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test
A novel, multianalyte test has been developed to identify central nervous system cancers from small samples of cerebrospinal fluid (CSF). In findings published in Cancer Discovery, the study authors reported that the test, called CSF-BAM, achieved a sensitivity of 81% and a specificity of 100%....
Lu-177 Dotatate in Progressive Metastatic Pheochromocytomas and Paragangliomas
In an interim analysis of a National Institutes of Health phase II study reported in the Journal of Clinical Oncology, Lin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) was active in progressive metastatic pheochromocytomas and paragangliomas (PPGLs). As stated by the investigators,...
Survey Finds Discordance Between Treatment Preferences and Clinical Care for Advanced Cancer
Patients with advanced cancer reported in survey responses that their treatment often focused on optimizing longevity over maintaining comfort and quality of life, despite their goals that prioritized the opposite, according to study results published in Cancer. Additionally, the findings...
Disparities in U.S. County–Level Cervical Cancer Screening Coverage Lead to Differences in Outcomes
In a study reported as a research letter in JAMA Network Open, Amboree identified U.S. counties with low or high cervical cancer screening coverage and associated risks of cervical cancer incidence and mortality. As stated by the investigators, “Recent research shows that cervical cancer incidence...
Analysis Shows No Major Racial Differences in Somatic Mutations of Triple-Negative Breast Cancer
A landmark study of the tumor mutational landscape of African American women with triple-negative breast cancer revealed that the mutational profile was largely similar with that of Asian and non-Hispanic White women, except for the presence of TP53 mutations in almost all African American...
Association of Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms in Childhood Cancer Survivors
In an analysis from the Children’s Oncology Group ALTE03N1 Study reported in the Journal of Clinical Oncology, Zhou et al found a fourfold increased risk of subsequent neoplasms (SNs) among childhood cancer survivors with germline pathogenic/likely pathogenic (P/LP) mutations. Study Details The...
Pembrolizumab Plus Chemotherapy vs Chemotherapy in Advanced Gastric Cancers: Final Survival Analysis From KEYNOTE-585
As reported in the Journal of Clinical Oncology by Shitara et al, the final overall survival analysis from the phase III KEYNOTE-585 study showed a numeric—but statistically nonsignificant—benefit with pembrolizumab plus chemotherapy vs chemotherapy in perioperative therapy for patients with...
What We Wish We Knew During Fellowship
July marks a significant transition for many professionals, particularly those beginning structured training programs on July 1. This article is designed to support new and current hematology-oncology fellows and trainees in making the most of their training experience. Although not all suggestions ...
ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR
ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The ASCO-sponsored TAPUR study is a...
Case 3: Cardiac Risk Stratification
This is Part 3 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss a challenging...
Case 2: CDK4/6 Inhibitor Choice in Medically Fragile Patients With Heart Failure
This is Part 2 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss managing...
Case 1: Management of Cardiovascular Risk Factors
This is Part 1 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss cardiovascular ...
Can Baseline Kidney Function Predict Chronic Kidney Disease After Cisplatin Treatment?
A population-based prognostic study published in JAMA Oncology found cisplatin treatment to be associated with a predictable decrease in the estimated glomerular filtration rate. According to Grant et al, their findings place patients with lower baseline kidney function at the highest risk for...
BWEL Weight-Loss Trial Reports Success for Patients With Breast Cancer at 1-Year Mark
Patients with stage II or III breast cancer who participated in a remote weight-loss intervention program lost an average of 4.7% of their baseline body weight after 1 year, whereas those in the education-only control group gained an average 1% of their baseline weight, according to a recent report ...
Which First-Line Systemic Therapy Balances Survival and Quality of Life in Advanced Hepatocellular Carcinoma?
A network meta-analysis reported in JAMA Oncology found that among first-line systemic therapy options, immunotherapy-based combinations—particularly atezolizumab plus bevacizumab—offered the most favorable therapeutic balance between survival benefit and quality-of-life preservation in...
Factors Influencing Symptom Burden in Pediatric Patients With Cancer: Insights From Routine Screening
As pediatric cancer survival rates continue to improve, attention has shifted to quality of life and symptom management. While a majority of patients experience problematic symptoms during treatment, these symptoms usually go undocumented and untreated. In a secondary analysis of a cluster...
Adding Everolimus to Chemotherapy Reduces Risk for Advanced Triple-Negative Breast Cancer
The addition of everolimus to standard carboplatin chemotherapy led to a 52% reduction in the risk of disease progression or death compared with carboplatin alone in patients with advanced triple-negative breast cancer, according to the results of a randomized phase II trial published in Breast...
Unmet Social Needs Distort Trust in Cancer Information, Study Shows
Researchers have found that unmet social needs was associated with less trust in cancer information received from doctors and the health-care system, according to study findings led by the American Cancer Society and published in Psycho-Oncology. “Public trust in health authorities is so essential ...
Basal Cell Carcinoma: Early Research on a Novel Topical Fluorescent Imaging Technique
A topical fluorescent molecular contrast agent, PARPi-FL (a poly[adenosine diphosphate ribose] polymerase 1 [PARP1] inhibitor–targeted fluorescent contrast agent) detected basal cell carcinoma through intact skin in as little as 5 minutes in ex vivo human tissues, according to new preclinical...
Rare Secondary Cancer After CAR T-Cell Therapy Successfully Treated, Case Report Shows
In a case presentation published in The New England Journal of Medicine, targeted treatment was successful for chimeric antigen receptor (CAR)-positive peripheral T-cell lymphoma developed after CAR T-cell therapy for multiple myeloma. Using advanced genomic, phenotypic, and functional profiling...
Racial and Ethnic Disparities in Guideline-Concordant Pancreatic Cancer Care Among Older Adults
In a study published in the Journal of Clinical Oncology Practice, Herb et al investigated racial and ethnic disparities in the receipt of guideline-concordant care among older adults with pancreatic cancer. Using data spanning 15 years, the researchers examined whether differences in treatment...
Bacterial Decolonization to Manage Acute Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma
Based on the results of a single-center phase III Chinese trial, which were published by Liao et al in JAMA Oncology, bacterial decolonization therapy with the antibiotic mupirocin may be an effective and cost-efficient strategy for alleviating severe acute radiation-induced oral mucositis in...
Study Finds Weather Disasters Increase Risk for U.S. Drug Supply Chain Disruption
In 2024, Hurricane Helene triggered a nationwide shortage of the country’s intravenous (IV) fluids after damaging a facility in North Carolina. A similar IV fluid shortage was caused when Hurricane Maria hit Puerto Rico in 2017. In a recent, nationwide study led by the American Cancer Society...
Smoldering Multiple Myeloma: How the Guidance Is Changing
Clinical trials have sought to determine the benefit of treating the precursors of multiple myeloma, but as the phenotypes and genomics of this entity are becoming better delineated, the wisdom of early intervention has remained confusing for clinicians. At the 2025 Debates and Didactics in...
Advancing Geriatric Oncology: A Personal and Professional Journey
I would like to begin by sharing a bit of my journey in geriatric oncology. Often, we do not hear the origin stories behind our professional paths, and I believe it is important to reflect on them. I have spent my entire academic career at Wake Forest University School of Medicine, where I arrived...
Can Beta Blockers Help Halt the Progression of Triple-Negative Breast Cancer?
Researchers have identified a molecular biomarker in triple-negative breast cancers that may inform when beta blockers can play a role in “switching off” tumor progression. These findings were published by Lam et al in Science Signaling. When stress hormones are released by the body’s nervous...
Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types
Researchers have uncovered that cancer cells degrade protective nerve coverings, causing cancer-induced nerve injury that can lead to chronic inflammation and resistance to anti–PD-1 immunotherapy, according to findings published in Nature. In exploring the role of perineural invasion and...
Nivolumab Plus RP1 Shows Durable Responses in Advanced Melanoma After PD-1 Inhibitor Resistance
Nivolumab in combination with RP1 (vusolimogene oderparepvec), a herpes simplex virus type 1–based oncolytic immunotherapy, showed activity in patients with advanced melanoma who experienced disease progression on standard anti‒PD-1‒based immunotherapy, according to findings from the phase I/II...
Identification of FAP-Expressing Tumors With Radiotracer
In a German single-center phase II trial reported in The Lancet Oncology, Pabst et al found that use of the fibroblast activation protein α (FAP)–directed radiotracer Ga-68–FAPi-46 for positron-emission tomography-computed tomography (PET-CT) has shown promising ability to identify FAP-expressing...
Adagrasib vs Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C–Mutated NSCLC
As reported in The Lancet by Barlesi et al, the phase III KRYSTAL-12 trial has shown a significant progression-free survival benefit with adagrasib over docetaxel in patients with previously treated locally advanced or metastatic KRAS G12C–mutated non–small cell lung cancer (NSCLC). Study Details...
Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd: Is It Safe?
Rechallenge with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) after grade 1 interstitial lung disease (ILD) appeared to be safe in a diverse real-world population, including many patients with breast cancer, as presented during the 2025 ASCO Annual Meeting.1 The ...
Rural and Urban Differences in Prostate Cancer Recurrence
In a study reported in JAMA Network Open, Balmaceda et al found that rural patients in North Carolina with newly diagnosed prostate cancer were more likely to experience biochemical recurrence than were urban patients. Study Details This cohort study used data from the North Carolina Prostate...
Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction
Investigators have developed and tested a hybrid reading strategy for screening mammography images with artificial intelligence (AI) that includes reads from radiologists and a stand-alone AI interpretation of mammograms with an uncertainty quantification. According to study findings published in...
Friends of Cancer Research Advances Work to Improve Interpretation of Interim OS Data in Oncology Trials
Friends of Cancer Research (Friends) launched the next phase of an initiative to improve how to interpret interim overall survival (OS) data in oncology clinical trials. Building on discussions during the Friends 2024 Annual Meeting, this new effort focuses on developing practical frameworks and...
Patient and Health-Care Professional Groups Express Support for Bipartisan Clinical Trial Bill
More than 100 organizations representing millions of patients with serious health conditions and health-care professionals sent a letter to Congress expressing their strong support for the Clinical Trial Modernization Act. Introduced in the House of Representatives in May 2025 by Reps. Raul Ruiz...
New Recommendations Released for Managing Aromatase Inhibitor–Induced Bone Loss
A group of experts from seven professional societies have published a joint position statement in the Journal of Bone Oncology on the management of aromatase inhibitor–associated bone loss (AIBL) as a guide for osteoporosis specialists and oncologists. This position statement acts as an update on...
Metastatic Colorectal Cancer: PROs With Sotorasib and Panitumumab vs Standard of Care
In an analysis from the phase III CodeBreaK 300 study reported in The Lancet Oncology, Modest et al found that sotorasib and panitumumab were associated with better patient-reported outcomes (PROs) than standard of care (SOC) with trifluridine plus tipiracil or regorafenib in patients with KRAS...
Locoregionally Advanced Nasopharyngeal Carcinoma: Comparison of Regimens Following Induction Chemotherapy
In a Chinese phase III trial reported in JAMA Oncology, Xue et al found that sequential chemoradiotherapy (SCRT) was noninferior to induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) in terms of failure-free survival in patients with locoregionally advanced nasopharyngeal...
Can Autoimmune Diseases Increase the Risk of Digestive System Cancer?
In a systematic review and meta-analysis published in the journal eClinicalMedicine, Reizner et al highlighted bias-minimized insights into the associations between autoimmune diseases, such as celiac disease, systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes, and the risk of...
Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC
“Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB non–small cell lung cancer [NSCLC],” according to Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and ...
Underlying Mechanisms of Chemoresistance in AML
Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cancer Discovery. They identified that the long-isoform RUNX1C's connection to BTG2 may enable cellular...
Effect of Hippocampal Avoidance in Prophylactic Cranial Irradiation in SCLC
In a phase II/III trial (NRG-CC003) reported in the Journal of Clinical Oncology, Gondi et al found that hippocampal avoidance (HA) in prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) did not improve delayed recall failure but was associated with benefits in...
Treatment-Resistant Melanoma: Novel Checkpoint Inhibitor Combination
New research published by Phadke et al in the Journal for ImmunoTherapy of Cancer found that adding a third immune-targeting drug to existing therapies may help to shrink tumors in laboratory models of treatment-resistant melanoma. Although immunotherapeutics have improved survival for many...
Can a Mitochondrial Antioxidant Drive Metastasis?
Mounting evidence suggests that the mitochondria may be a driving force behind cancer. A new report points to the mitochondrial metabolite glutathione, highlighting its central role in helping breast cancer cells break away from the primary tumor, travel through the body, and take root in other...
Endocrine Therapy With Aromatase Inhibitor for Postmenopausal Women With Breast Cancer
In a patient-level meta-analysis reported in The Lancet, Braybrooke et al of the Early Breast Cancer Trialists’ Collaborative Group found that adding subsequent years of aromatase inhibitor treatment (AIT) for women with early estrogen receptor–positive breast cancer who had already received 5...
Case 3: Patient With Myelofibrosis on Active Treatment
This is Part 3 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...
